Analyzing miRNAs in COVID-19 patients
Official title: Circulating Mi-RNA Associated With Disease Severity and Outcome in COVID-19 Patients
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06881160 · Data updated 2026-11-12
This study is trying to see if certain tiny molecules in the blood can help predict how severe COVID-19 will be and if it might lead to death in adults who have tested positive for the virus.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 49 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma, RM) |
| Status | Recruiting |
| Started | March 1, 2020 |
| Main results expected | December 31, 2025 |
| Study ends | December 1, 2027 |
| Registry record updated | March 18, 2025 |
| Trial ID | NCT06881160 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of SARS-CoV-2 infection.
✕Probably not a fit
Patients who are pregnant will not benefit from this study as they are excluded from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the role of microRNAs (miRNAs) in patients diagnosed with COVID-19, focusing on their association with disease severity and mortality. By analyzing miRNA profiles in individuals confirmed to have SARS-CoV-2 infection, the study seeks to identify potential biomarkers that could help predict clinical outcomes. Participants will be adults aged 18 and older who have tested positive for the virus, while pregnant women will be excluded from the study. The research will be conducted at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that help predict the severity of COVID-19, potentially guiding treatment decisions.
How similar studies have gone: While the analysis of miRNAs in relation to COVID-19 is a relatively novel approach, similar studies have shown promise in identifying biomarkers for other diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years * diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs Exclusion Criteria: * pregnant women
Where it's running
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Rm, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults
This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.
-
Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals
A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.
-
Secutrelvir for nonhospitalized COVID-19 in teens and adults
This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.
-
Virological Monitoring of Seasonal Respiratory Infections in France
This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.
-
COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry
This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.
-
MDX2301 in healthy adults and adults at higher risk for severe COVID-19
This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.